Massachusetts Department of Public Health
Immunization Program

Summary of ACIP Recommended Groups for Vaccination, 2015[1]

☐ Updates and changes from the previous version are highlighted in yellow.

Vaccine[2]	Recommended Groups for Vaccination
DTaP	1. All children younger than 7 years of age Note: DTaP vaccine is not licensed for individuals 7 years of age or older
DT	1. Children less than 7 years of age with true and valid contraindications to pertussis vaccine
Hepatitis A	1. All children 12 through 23 months of age. 2. Catch-up of unvaccinated children 2 through 18 years of age. Such programs might be warranted if there are ongoing outbreaks among children or adolescents. 3. High-risk individuals including: • Men who have sex with men • Users of injection and illicit drugs • Persons with chronic liver disease, including hepatitis C • Persons with clotting factor disorders • Persons working with hepatitis A virus (HAV) in a research laboratory or with HAV infected primates. No other occupations have been demonstrated to increase the risk of HAV infection. • Persons traveling to, or working in, anywhere EXCEPT the U.S., Western Europe, New Zealand, Australia, Canada, and Japan. Persons 2 years of age and older who live in communities experiencing outbreaks of HAV (if indicated by local epidemiologic data). • Persons in close contact with an international adoptee during the first 60 days after arrival in the U.S. from a country of high or intermediate endemicity. 4. All other persons seeking protection from HAV infection. 5. Post-exposure for healthy persons 12 months through 40 years of age, given within 14 days of exposure. (For persons older than 40 years of age: immune globulin (IG) is preferred post exposure, vaccine can be used if IG is not available. Children less than 12 months, immunocompromised individuals, those with chronic liver disease who have contraindications for hep A vaccine, should receive IG post exposure).

[1]The information in this table is a summary of the Advisory Committee on Immunization Practices (ACIP) recommendations. Complete ACIP recommendations for each vaccine, including the number of doses to be administered and the timing of doses, can be accessed at the ACIP website http://www.cdc.gov/vaccines/acip/index.html

[2] Licensed combination vaccines may be used whenever any components of the combination are indicated and other components of the vaccine are not contraindicated and if approved by the FDA for that dose of the series. Package inserts for all approved vaccine formulations can be found at: http://www.fda.gov/BiologicsBloodVaccines/vaccines/ApprovedProducts/ucm093830.htm

Hepatitis B	1. Routine Pediatric and Adolescent Recommendations • Infants born to mothers who are hepatitis B surface antigen (HBsAg)-positive. • All infants. • All unvaccinated children and adolescents less than 19 years of age. 2. Adult Recommendations a. Persons at risk for infection by sexual exposure: • Sex partners of HBsAg-positive persons. • Sexually active persons not in a long-term, mutually monogamous relationship (e.g., persons with more than one sex partner during the previous 6 months). • Persons seeking evaluation or treatment for a sexually transmitted disease. • Men who have sex with men. b. Persons at risk for infection by percutaneous or mucosal exposure to blood: • Current or recent injection-drug users. • Household contacts of HBsAg-positive persons. • Residents and staff of facilities for developmentally disabled persons. • Health-care and public safety workers with reasonably anticipated risk for exposure to blood or blood-contaminated body fluids. (Note: Employers covered by federal OSHA regulations are responsible for supplying hepatitis B vaccine to their at-risk employees.) • Persons with end-stage renal disease, including predialysis, hemodialysis, peritoneal dialysis, and home dialysis patients. c. Other: • International travelers to regions with high or intermediate levels (HBsAg prevalence of ≥2%) of endemic hepatitis B virus (HBV) infection. • Persons with chronic liver disease. • Persons with diabetes < 60 years as soon as feasible after diagnosis. • Persons with diabetes ≥ 60 years at clinician's discretion, considering: 1) need for assisted blood glucose monitoring in long-term care facilities; 2) likelihood of acquiring hepatitis B infection and its complications or chronic sequelae; and 3) likelihood of immune response to immunization. • Persons with HIV infection. • All other persons seeking protection from HBV infection. d. High risk settings: (Settings where vaccination is recommended for all adults, because a high proportion of individuals have risk factors.) • STD treatment facilities. • HIV testing and treatment facilities. • Facilities providing drug-abuse treatment and prevention services. • Health-care settings providing services for injection-drug users or men who have sex with men. • Correctional facilities. • End-stage renal disease programs and facilities for chronic hemodialysis patients. • Institutions and nonresidential daycare facilities for persons with developmental disabilities.

Hib	1. All children younger than 5 years of age. • The number of doses needed to complete the schedule depends on the age of the child and the formulation used 2. Hib vaccine is not routinely recommended for those 5 years and older unless they are considered to be at high risk for invasive Hib disease. Groups at high risk include: sickle cell disease, functional or anatomic asplenia, leukemia, malignant neoplasms, other immunocompromising conditions, HIV infected children 3. Recommendations for high risk groups are as follows; • Age <12 months: follow routine schedule. • Age 12-59 months: • If unimmunized or received 0 or 1 dose before 12 months, they should receive 2 doses 8 weeks apart; • If received ≥2 doses before age 12 months, they should receive 1 dose 8 weeks after last dose; • If completed a primary series and received a booster dose at ≥12 months, no additional doses are needed. • Age younger than 5 years undergoing chemotherapy or radiation: • If routine Hib doses administered ≥14 days before starting therapy, revaccination is not required; • If a Hib dose is administered < 14 days before starting therapy or given during therapy, repeat those doses starting at least 3 months following therapy completion. • Age ≥15 months undergoing elective splenectomy: if unimmunized, give 1 dose ≥2 weeks prior to procedure. • Asplenic children 5 years and older and adults: if unimmunized, give 1 dose (if undergoing procedure give ≥2 weeks prior). • Hematopoietic stem cell transplants of all ages and regardless of Hib vaccination history: 3 doses (at least 4 weeks apart) are recommended beginning 6-12 months after transplant. • HIV infected children: 1 dose of Hib vaccine is recommended for previously unvaccinated children 5 through 18 years of age with HIV infection. But, it is **no** longer recommended for previously unvaccinated HIV infected adults.
Human Papillomavirus 9-valent (9vHPV) (Gardasil 9) 4-valent (4vHPV) Gardasil 2-valent (2vHPV) Cervarix	1. All females and males entering 7th grade (11-12 years of age). The vaccination series can be started in females and males as young as 9 years of age. 2. Routine "catch-up" vaccination for all females 13 through 26 years of age. 3. Routine "catch-up" vaccination for males 13 through 21 years of age. 4. "Catch-up" vaccination for high risk males 22 through 26 years of age (immunosuppressed, men who have sex with men, HIV-infected). 5. Permissive "catch-up" for non-high risk males 22-26 years. 6. HPV vaccine is recommended for all females and males through 26 years who are immunocompromised who did not get the vaccine when they were younger. Note: 9vHPV and 4vHPV vaccines are approved for use in **both** females and males. 2vHPV vaccine is **only** approved for use in females.

Influenza
 	
Inactivated Influenza Vaccine (IIV)
 	
Live Attenuated Influenza Vaccine (LAIV)
	1. All persons aged 6 months and older every year
	• Children aged 6 months through 8 years who have previously received 2 or more doses of trivalent or quadrivalent influenza vaccine as of July 1, 2015, need only 1 dose for the 2015-2016 season. The 2 previous doses do not need to have been given during the same season or consecutive seasons. For additional guidance on doses needed for children < 9 years of age, follow the 2015-16 guidance at: http://www.cdc.gov/vaccines/acip/index.html
	• This year, there is no preferential recommendation for any one age-appropriate approved flu formulation over another. The ACIP did not renew its preferential recommendation for influenza vaccine (LAIV) for use in healthy children 2-8 years of age. **Vaccination should not be delayed for a specific vaccine preparation.**
	
	2. People at increased risk for influenza-related complications:
	• All children 6 months through 4 years of age.
	• All persons ≥ 50 years of age.
	• People 6 months - 18 years of age who are receiving long-term aspirin therapy.
	• Women who will be pregnant during influenza season and postpartum women.
	• People ≥ 6 months of age who have:
	  • Chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, hepatic, neurological, hematologic, or metabolic disorders, including diabetes;
	  • Immunosuppression (includes immunosuppression caused by medications or HIV);
	  • Any condition (e.g., cognitive dysfunction, spinal cord injuries, seizure disorders, or other neuromuscular disorders) that can compromise respiratory function or the handling of respiratory secretions or that can increase the risk of aspiration.
	• Residents of nursing homes and other chronic-care facilities.
	• American Indians/Alaska Natives
	• People who are morbidly obese (BMI ≥ 40)
	
	3. Persons who can transmit influenza to persons at high risk:
	• Health care personnel (HCP), employees of assisted living facilities, people who provide home care to people at risk, medical emergency response workers, and students in these professions.
	• Household contacts (including children) and caregivers of children aged < 5 years and adults ≥ 50 years, and contacts of people at risk for complications from flu (listed above).
	
	4. Persons at increased risk of exposure to influenza:
	• Persons who provide essential community services.
	• Students and other persons in institutional settings (e.g., dormitories).
	• Certain travelers.
	
	Note: For most healthy, non pregnant persons, either LAIV or IIV may be used. LAIV should not be used for those who are pregnant, immunosuppressed, have asthma or any other medical condition that predisposes them to influenza complications.

Meningococcal Quadrivalent (MenACWY) Vaccines Meningococcal Conjugate vaccine (MCV4**):** Menactra licensed for ages 9 months through 55 years, Menveo licensed for 2 months through 55 years Meningococcal Polysaccharide vaccine (MPSV4): licensed for ages 2 years and older	1. All adolescents 11 through 18 years of age. • One dose routinely administered at 7th grade entry (11-12 years of age) • Booster dose for those 16 - 18 years of age (minimum interval between doses is 8 weeks) • Routine catch-up of adolescents 13 through 18 years of age who have not received a 1st dose meningococcal vaccine (No booster if primary dose received on or after 16 years of age years) 2. College freshmen through age 21 years • One dose of MCV no more than 5 years before enrollment in college, particularly if they are new residential students • One booster dose before enrollment if they received their primary dose prior to age 16 years 3. Persons with risk for exposure: travelers to countries where meningococcal disease is hyperendemic or epidemic, military recruits and microbiologists working with *N. meningitidis.* • One dose if not previously vaccinated • Booster at ≥3 years for children aged 2 through 6 years; booster at ≥5 years for persons aged 7 years and older, if they remain at risk 4. High risk children 2-23 months of age who: have persistent complement component deficiencies; functional or anatomic asplenia (including sickle cell); are travelers to countries where meningococcal disease is hyperendemic or epidemic; or live in communities or institutions where outbreaks are occurring: • Primary series: 2 - 4 doses, depending on age and formulation (see 'Note' below). • Give boosters at ≥3 years for children aged 2 through 6 years; and at ≥ 5 years for persons aged 7 years and older 5. Persons ≥ 2 years with persistent complement deficiency or anatomic asplenia (including those with sickle cell) • Primary series: 2 doses, 2 months apart • Separate PCV13 and MCV4 by ≥ 4 weeks • Give boosters at ≥3 years for children aged 2 through 6 years; at ≥5 years for persons aged 7 years and older 6. HIV-infected persons older than age 2 years, if they have another indication for meningococcal vaccines • Primary series: 2 doses, 2 months apart • Give boosters at ≥3 years for children aged 2 through 6 years; at ≥5years for persons aged 7 years and older 7. Persons who wish to decrease their risk for meningococcal disease may elect to be vaccinated. Note: Because of the high risk for invasive pneumococcal disease, children with functional and anatomic asplenia (including sickle cell disease) should **NOT** be immunized with Menactra before 2 years -- and it should be separated by ≥4 weeks after completion of all PCV13 doses to avoid potential interference with immune response to PCV13. These children can and should receive Menveo.

Meningococcal B (MenB) Vaccines MenB-FHbp (Trumenba) MenB-4C (Bexsero)	1. Persons aged ≥10 years who are at increased risk for meningococcal disease due to serogroup B: • Persons with persistent complement component deficiencies (including: inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or taking eculizumab [Soliris®]). • Persons with anatomic or functional asplenia (including: sickle cell). • Microbiologists routinely exposed to isolates of *Neisseria meningitidis*. • Persons identified as at increased risk because of a serogroup B meningococcal disease outbreak as determined public health authorities. (The above recommendation is a Category A recommendation which means MenB vaccine is recommended for everyone in these high risk groups.) 2. In addition, MenB vaccine series *may* be administered to adolescents and young adults 16 through 23 years of age to provide short term protection against most strains of serogroup B meningococcal disease. The preferred age for MenB vaccination in this age group is 16 through 18 years of age in order to maximize protection during the highest risk period. (This is a Category B recommendation which means that it allows for individual clinical decision making.) Vaccine Schedules • Bexsero (MenB-4C) should be administered as a 2-dose series (0, ≥1 month). • Trumenba (MenB-FHbp) should be administered as a 3-dose series (0, 2, 6 months). • The **same** vaccine product must be used for all doses. • MenB-FHbp or MenB-4C may be administered concomitantly with MenACWY vaccines and other adolescent vaccines, but at a different anatomic site, if feasible.
MMR	1. All children 12 months through 18 years of age. • The 1st dose is routinely administered at 12 through 15 months of age. • The 2nd dose is routinely administered at kindergarten entry (4-6 years of age). • A 2nd dose "catch-up" for all children and adolescents who previously received 1 dose. 2. For children 6-11 months with international travel, administer 1 dose. These children should be revaccinated at age 12-15 months. If remain in area that is high risk, revaccinate at 12 months, with a 2nd dose ≥ 4 weeks later. 3. All individuals 19 years of age and older, who were born in or after 1957: 1 dose 4. All people aged ≥ 12 months with HIV infection who do not have evidence of MMR immunity or evidence of severe immunosuppression. 5. Adults at high risk (i.e., persons who work in health-care facilities, international travelers, and students at post-high school educational institutions): 2 doses 6. All health-care workers: 2 doses are recommended, regardless of year of birth 7. Women of childbearing age without documented vaccination or laboratory evidence of immunity 8. Any contact of a suspect or confirmed case ≥ 12 months without documentation of 2 doses of MMR vaccine. For infants aged 6 through 11 months, MMR vaccine can be administered in place of IG, if administered within 72 hours of exposure. Such infants must receive a normal 2-dose series beginning ≥12 months.

Pneumococcal Conjugate (PCV13)	1. Healthy children younger than 5 years of age should complete 4-dose PCV13 series. 2. Healthy children aged 24 through 59 months with any incomplete PCV (PCV7 or PCV13) schedule before age 24 months: 1 dose of PCV13 3. Children 24 through 71 months of age with underlying medical conditions (including chronic medical conditions, CSF fluid leaks, cochlear implants, immunocompromising conditions, HIV, sickle cell, asplenia): • Unvaccinated or any incomplete schedule of <3 doses of PCV13: 2 doses of PCV13 given 8 weeks after most recent PCV dose and 8 weeks apart. • Any incomplete schedule of 3 doses of PCV13: 1 dose of PCV13 ≥ 8 weeks after most recent PCV dose. 4. A single dose of PCV13 is recommended for children 6 through 18 years of age and adults ≥ 19 years of age who have never been vaccinated with: a. Functional or anatomic asplenia b. HIV infection or other immunocompromising conditions c. Cochlear implant d. Cerebrospinal fluid leak 5. A single dose is recommended for all adults 65 years of age or older: • A dose of PCV13 followed by PPSV23 should be administered routinely **in a series** to all immunocompetent adults aged ≥65 years. **PCV13** should be administered **only once** for all adults. Specific recommendations are based on a person's previous pneumococcal vaccine history. • Persons who are pneumococcal vaccine-naïve. Adults aged ≥65 years who have not previously received pneumococcal vaccine or whose previous vaccination history is unknown should receive a single dose of PCV13 first, followed by a dose of PPSV23. The dose of PPSV23 should be given **≥1 year** after a dose of PCV13. If PPSV23 cannot be given during this time window, the dose of PPSV23 should be given during the next visit. • Persons previously vaccinated with PPSV23. Adults aged ≥65 years who have previously received ≥1 doses of PPSV23 also should receive a single dose of PCV13 if they have not yet received it. A dose of PCV13 should be given **≥1 year** after receipt of the most recent PPSV23 dose. For those for whom an additional dose of PPSV23 is indicated, this subsequent PPSV23 dose should be given **≥1 year** after PCV13 and **≥5 years** after the most recent dose of PPSV23. **Timing:** • The two vaccines should not be co-administered. If doses of PPSV23 and PCV13 are inadvertently given on the same day or earlier than the recommended interval, those doses do not need to be repeated. • Adults 19 years and older at increased risk for pneumococcal disease who received a dose of PCV13 at 64 years or younger should **not** receive another dose of PCV13 at 65 years or older. • For adults ≥65 years with immunocompromising conditions, functional or anatomic asplenia, CSF fluid leaks or cochlear implants, the recommended interval between a dose of PCV13 and PPSV23 remains at ≥8 weeks. Note: For additional information on the appropriate intervals, including when PPSV23 is given before PCV13, **see the section on timing under PPSV23 vaccine below.**

Pneumococcal Polysaccharide (PPSV23)	1. All adults 65 years of age and older. 2. Persons 2 through 64 years of age: • With chronic illnesses, including cardiovascular disease, pulmonary disease, diabetes, alcoholism, liver disease, renal failure or nephrotic syndrome and CSF fluid leaks. • With anatomic or functional asplenia (e.g., sickle cell disease and other hemoglobinopathies, congenital or acquired asplenia, splenic dysfunction, or splenectomy). • Who have or are scheduled to have cochlear implants. • Who are immunocompromised, including those with congenital immunodeficiency, HIV infection, leukemia, lymphoma, multiple myeloma, Hodgkin disease, generalized malignancy, organ or bone marrow transplantation and those with immunosuppression caused by chemotherapy, radiation therapy or high-dose, long-term corticosteroids (including children with asthma on long-term corticosteroids). • Who live in long-term care facilities 3. Persons 19 years of age and older with asthma 4. Persons 19 years of age and older who smoke 5. In special situations, public health authorities may recommend PPSV23 for some groups of Alaska Natives and American Indian children 24 through 59 months of age and adults 50 through 64 years of age **One time revaccination after five years for:** • People aged 19 through 64 years of age with: • Functional or anatomic asplenia (including sickle cell disease) • Immunocompromising conditions (including HIV infection) • Chronic renal failure or nephrotic syndrome in adults • People aged ≥ 65, if they were vaccinated 5 or more years previously, and were aged younger than 65 years at the time of the previous dose • No further doses needed for those vaccinated at ≥ 65 years **Timing of vaccination for 'special highest risk' children 2-18 years and adults ≥19 years who are recommended to receive both PCV13 and PPSV23 (functional or anatomic asplenia, sickle cell, HIV infection, immunocompromising conditions, chronic renal failure or nephrotic syndrome, CSF fluid leaks, cochlear implants) are outlined below:** • For the 'special highest risk' of all ages ideally administer PCV13 **first** and then administer PPSV23 at least 8 weeks later. This interval minimized the risk window for invasive pneumococcal disease caused by serotypes unique to PPSV23 in these highly vulnerable groups. • If the individual is 2-18 years of age and has already received PPSV23, administer PCV13 at least 8 weeks later. • If the individual is ≥19 years and has already received PPSV23, administer PCV13 at least 1 year later. • When cancer chemotherapy, other immunosuppressive therapy or splenectomy is being considered, please vaccinate ≥ 2 weeks before. Vaccination during chemotherapy or radiation therapy should be avoided. • The PPSV23 and PSV13 should not be co-administered. If doses of PPSV23 and PCV13 are inadvertently given on the same say or earlier than the recommended interval, those doses should **not** be repeated.

Inactivated Polio (IPV)	1. 4-dose series for children less than 18 years of age Administer the final dose in the IPV series at age ≥4 years regardless of the number of previous doses and at least ≥ 6 months after the previous dose. • A 4th dose is not necessary if the 3rd dose was administered at ≥4 years and at least ≥ 6 months after the previous dose. • If both OPV and IPV were administered as part of the series, a total of 4 doses should be administered, regardless of child's age. 2. Vaccination of adults in the following high-risk groups is recommended with a 3-dose series. Routine poliovirus vaccination of adults (i.e., persons aged ≥18 years) residing in the United States is not necessary. Those traveling to areas with endemic or epidemic polio. • Laboratory workers who handle poliovirus. • Healthcare workers caring for polio patients.
Rotavirus	All infants 6 weeks through 8 months 0 days of age. Note: Rotavirus vaccine is not licensed for use in infants older than 8 months 0 days of age.
Td	1. Persons aged 7 years and older without a primary series of tetanus-diphtheria containing vaccine.* 2. A booster dose every 10 years.* 3. Wound management of those 7 years of age and older.* 4. Persons traveling to countries at high risk for diphtheria.* 5. Pregnant women who are under-immunized. 6. Those at occupational risk who are under-immunized.* *Substitute 1 dose of Tdap for Td. Note: Td vaccine is not licensed for use in individuals less than 7 years of age.
Tdap Boostrix licensed for ages ≥ 10 years of age Adacel licensed for ages 10-64 years of age	Tdap is recommended for use as a *single* booster dose except in pregnant women. **1. Adolescents (10 through 18 years of age).** Substitute 1 dose of Tdap for Td in: • All adolescents entering 7th grade (11-12 years of age). • Adolescents 13 through 18 years of age who have not yet received a dose of Tdap. • Children 7 -10 years of age who are not fully vaccinated against pertussis* and for whom no contraindication to pertussis vaccine exists should receive a single dose of Tdap. • Children 7 - 10 years of age who have never been vaccinated against tetanus, diphtheria, or pertussis or who have unknown vaccination status should receive a series of three vaccinations containing tetanus and diphtheria toxoids. The first of these three doses should be Tdap. • Individuals who are un- or under-vaccinated for wound prophylaxis, **including pregnant teens.** • Individuals who have been exposed to pertussis or in an outbreak setting. Fully vaccinated is defined as 5 doses of DTaP or 4 doses of DTaP, if the fourth dose was administered on or after the fourth birthday **2. Adults (≥ 19 years of age).** A *single* dose of Tdap to replace a single dose of Td. • Special emphasis on adults with close contact with infants less than 12 months of age, including those ≥65 years. **(Continued on next page)**

Tdap Continued	• Parents, particularly in the postpartum period. • Grandparents • Child care workers. • Health-care providers • Individuals un- or under-vaccinated for wound prophylaxis, **including pregnant women**. • Individuals who have been exposed to pertussis or in an outbreak setting. **3. Pregnant women.** Tdap should be administered during each pregnancy, irrespective of the patient's history of receiving Tdap. To maximize antibody transfer to the infant, administer Tdap between 27 and 36 weeks gestation, although Tdap may be given any time during pregnancy. If not administered during pregnancy, Tdap should be administered immediately postpartum for women not previously vaccinated with Tdap. Note: Administer Tdap regardless of interval since last tetanus- or diphtheria-toxoid vaccine. Do not miss an opportunity to vaccinate persons $\geq$ 65 years. ACIP recommends permissive use of Adacel, if Boostrix not available for this age group
Varicella	1. All preschool and school-aged children: 2 doses of varicella-containing vaccine • The 1st dose routinely administered at 12 through 15 months of age. • The 2nd dose routinely administered at kindergarten entry (4 through 6 years of age). 2. Children, adolescents and adults without evidence of immunity to varicella: 2 doses of varicella vaccine. 3. A 2nd dose "catch-up" vaccination is recommended for children, adolescents, and adults who previously had received 1 dose. 4. Susceptible contacts of confirmed or suspect cases of varicella, including those who have previously received only 1 dose. **Give special consideration to:** • Susceptible health-care workers. • Susceptible postpartum women and non-pregnant women of child-bearing age • Susceptible child care providers, teachers of young children, residents/staff in institutional settings, including correctional facilities. • Susceptible college students and military personnel. • Susceptible contacts of immunocompromised individuals, regardless of age. • Susceptible adolescents and adults living in households with children. • Susceptible international travelers. • Residents and staff of institutional settings, including shelters, group homes, prisons and jails.
Zoster (Shingles)	All adults $\geq$ 60 years* of age including: • Those in long-term care facilities • Those $\geq$ 60 years anticipating immunodeficiency due to initiation of treatments or progression of illness (give $\geq$ 14 days before treatment--some experts recommend 1 month) • Persons with a prior episode of shingles • Persons with chronic medical conditions (e.g., renal failure, diabetes, rheumatoid arthritis) **unless** a contraindication or precaution exists for their condition. **Note:** Screening for a history of varicella disease, varicella vaccination or serologic testing is not recommended or necessary prior to administration of zoster vaccine. *Although zoster vaccine is licensed for use in those 50 years of age and older, the ACIP recommends that vaccination begin at 60 years of age.